A Phase I Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer

202031 citationsJournal Articlebronze Open Access

Authors

Richard D. Kim · Moffitt Cancer Center

Elaine Tan · Moffitt Cancer Center

Emily Wang · Moffitt Cancer Center

Amit Mahipal · Mayo Clinic

Dung‐Tsa Chen · Moffitt Cancer Center

Biwei Cao · Moffitt Cancer Center

Fadzai Masawi ·

Abstract

Trametinib and sorafenib can be safely administered up to trametinib 1.5 mg daily and sorafenib 200 mg twice a day with limited anticancer activity in advanced HCC.

Topics & Keywords

Hepatocellular Carcinoma Treatment and Prognosis Cancer Mechanisms and Therapy PI3K/AKT/mTOR signaling in cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Oncologist

Volume 25, Issue 12, pp. e1893-e1899

DOI: 10.1634/theoncologist.2020-0759

Field-Weighted Citation Impact: 2.28